- Home
- OPTN vs BCAB Comparison
OPTN vs BCAB Comparison
Compare OPTN & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- BCAB
- Stock Information
- Founded
- OPTN 2010
- BCAB 2007
- Country
- OPTN United States
- BCAB United States
- Employees
- OPTN N/A
- BCAB N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- OPTN Health Care
- BCAB Health Care
- Exchange
- OPTN Nasdaq
- BCAB Nasdaq
- Market Cap
- OPTN 99.7M
- BCAB 101.0M
- IPO Year
- OPTN 2017
- BCAB 2020
- Fundamental
- Price
- OPTN $0.46
- BCAB $1.72
- Analyst Decision
- OPTN Strong Buy
- BCAB Buy
- Analyst Count
- OPTN 3
- BCAB 2
- Target Price
- OPTN $3.00
- BCAB $5.00
- AVG Volume (30 Days)
- OPTN 617.5K
- BCAB 914.1K
- Earning Date
- OPTN 11-12-2024
- BCAB 11-07-2024
- Dividend Yield
- OPTN N/A
- BCAB N/A
- EPS Growth
- OPTN N/A
- BCAB N/A
- EPS
- OPTN N/A
- BCAB N/A
- Revenue
- OPTN $75,672,000.00
- BCAB $11,000,000.00
- Revenue This Year
- OPTN $24.44
- BCAB N/A
- Revenue Next Year
- OPTN $49.00
- BCAB N/A
- P/E Ratio
- OPTN N/A
- BCAB N/A
- Revenue Growth
- OPTN 5.13
- BCAB N/A
- 52 Week Low
- OPTN $0.44
- BCAB $1.14
- 52 Week High
- OPTN $2.10
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- OPTN 28.38
- BCAB 47.44
- Support Level
- OPTN $0.50
- BCAB $2.02
- Resistance Level
- OPTN $0.81
- BCAB $2.53
- Average True Range (ATR)
- OPTN 0.06
- BCAB 0.21
- MACD
- OPTN -0.02
- BCAB -0.01
- Stochastic Oscillator
- OPTN 3.23
- BCAB 5.79
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.